Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 7 stocks made the list for top value stocks in the Advanced Medical Equipment & Technology industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Latest Advanced Medical Equipment & Technology Stock News

Before choosing which top Advanced Medical Equipment & Technology stock to buy, be sure to conduct proper due diligence: analyze various financial metrics and look at historical data, public statements and news coverage.

We have a positive fundamental outlook for the life sciences tools & services (LSTS) sub-industry for the next year. In 2021, we expect adjusted EPS growth to rise by mid to high teens, reversing the subpar growth seen in 2020, assuming a healthier economic environment globally. We expect R&D spending to continue to improve during 2021 as we are seeing most of the clinical research that was put on hold resuming. We expect the increase in demand for Covid-19 testing and related products and services to remain until the pandemic is fully under control globally and continue to be a considerable tailwind for a number of LSTS companies. Risk factors we see are slower biopharma R&D spending growth and prolonged uncertainty in certain parts of the world due to Covid-19 as new variants of the virus emerged. The National Institutes of Health (NIH) budget has been growing over the last three years, increasing funding for academic and government labs. This in turn helps drive sales growth for many LSTS companies that supply these labs. The NIH budget for fiscal 2021 (Sep.) rose 3.0%, which is lower than 5.9% for fiscal 2020 and 5.4% growth for fiscal 2019. Yet, the NIH budget grew at a CAGR of 5.8% from 2016 through 2021, a sharp increase from the flat budget growth from 2012 through 2015. The Covid-19 pandemic had a considerable impact on the sub-industry in 2020 due to the moderation in biopharma R&D spending, disruptions in clinical sites accessibility, slowdown in patient enrollments for clinical studies, and a decline in the demand for large-scale life sciences equipment with investments delayed. Yet, we saw gradual improvement throughout 2020 and a solid recovery in Q1, as countries re-opened and operations resumed with a faster-thananticipated recovery in Asia (especially China) as a result of pent-up demand, in our view. Yet, despite the increased pace of Covid-19 vaccinations in the U.S., with the emergence of new more dangerous variants and the slower pace of vaccinations in the rest of the world, the speed and sustainability of the recovery remain unclear, in our view.

Why Focus on Undervalued Advanced Medical Equipment & Technology Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

7 Undervalued Advanced Medical Equipment & Technology Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 7 undervalued stocks in the Advanced Medical Equipment & Technology industry for Thursday, January 12, 2023. Let’s take a closer look at their individual scores to see how they measure up against each other and the Advanced Medical Equipment & Technology industry median.

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

BIOLASE Inc’s Value Grade

Value Grade:

BIOLASE, Inc. is a provider of advanced laser systems for the dental industry. The Company develops, manufactures, markets and sells laser systems, which provides helps to dental practitioners and their patients. The Company’s systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons and other dental specialists to perform a range of dental procedures, including cosmetic, restorative and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft tissue) systems. Its Waterlase brand uses a patented combination of water and laser energy and performs using drills, scalpels and other traditional dental instruments for cutting soft and hard tissue. It offers its diode laser systems to perform soft tissue, pain therapy and cosmetic procedures, including teeth whitening. It has approximately 301 issued and 38 pending United States and international patents.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

BIOLASE Inc has a Value Score of 83, which is considered to be undervalued.

When you look at BIOLASE Inc’s price-to-sales ratio at 0.07 compared to the industry median at 3.50, this company has a lower price relative to revenue compared to its peers. This could make BIOLASE Inc’s stock more attractive for value investors.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. BIOLASE Inc’s shareholder yield is lower than its industry median ratio of (2.32%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. BIOLASE Inc’s price-to-book ratio is lower than its industry median ratio of 2.48. This could make BIOLASE Inc more attractive to investors looking for a new addition to their portfolio.

Hyperfine Inc’s Value Grade

Value Grade:

Hyperfine, Inc. is a medical device company. The Company provides a portable Swoop system, which is a bedside Magnetic resonance imaging (MRI) system. The Company designed Swoop to enable rapid diagnoses and treatment for every patient regardless of resources, or location. The Swoop portable magnetic resonance imaging system produces images at a low magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by an iPad. Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments, operating rooms outside the sterile field and intensive care units, among others. The Company's Liminal platform is being developed to aid in the diagnosis and management of brain disorders.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Hyperfine Inc has a Value Score of 72, which is considered to be undervalued.

Hyperfine Inc’s price-to-book ratio is higher than its peers. This could make Hyperfine Inc less attractive for value investors when compared to the industry median at 2.48.

You can read more about Hyperfine Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Medigus Ltd - ADR’s Value Grade

Value Grade:

Medigus is a Israel-based medical device company specializing in developing minimally invasive endosurgical tools and imaging solutions across medical and industrial applications. The Company developed a range of micro video cameras underr micro ScoutCam portfolio of products and the Medigus Ultrasonic Surgical Endostapler, or MUSE system endoscopic device for the treatment of gastroesophageal reflux disease (GERD)

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Medigus Ltd - ADR has a Value Score of 75, which is considered to be undervalued.

Medigus Ltd - ADR’s price-to-book ratio is higher than its peers. This could make Medigus Ltd - ADR less attractive for value investors when compared to the industry median at 2.48.

You can read more about Medigus Ltd - ADR’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Nuwellis Inc’s Value Grade

Value Grade:

Nuwellis, Inc. is a medical device company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex SmartFlow and the Aquadex FlexFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid (primarily excess salt and water) from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and an LCD screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filter, sensors, and connectors that contain and deliver the blood from and back to the patient; and a disposable catheter.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Nuwellis Inc has a Value Score of 91, which is considered to be undervalued.

Nuwellis Inc’s price-to-book ratio is higher than its peers. This could make Nuwellis Inc less attractive for value investors when compared to the industry median at 2.48.

You can read more about Nuwellis Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Precipio Inc’s Value Grade

Value Grade:

Precipio, Inc. is a healthcare solutions company that is focused on cancer diagnostics. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D;) facilities are located in New Haven, Connecticut and Omaha.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Precipio Inc has a Value Score of 71, which is considered to be undervalued.

Precipio Inc’s price-to-book ratio is higher than its peers. This could make Precipio Inc less attractive for value investors when compared to the industry median at 2.48.

You can read more about Precipio Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Vaso Corp’s Value Grade

Value Grade:

Vaso Corporation is principally engaged in operating healthcare equipment and information technology industries. The Company's segments include IT, Professional sales service and Equipment. The IT segment operates through the Company's subsidiary, VasoTechnology, Inc., which is focused on healthcare IT and managed network technology service. The Professional sales service segment operates through the Company's subsidiary, Vaso Diagnostics, Inc. doing business as VasoHealthcare, which is focused on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. The Equipment segment is focused on designing, manufacturing, selling and servicing of medical devices, operating through the Company's subsidiary, VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Vaso Corp has a Value Score of 91, which is considered to be undervalued.

Vaso Corp’s price-earnings ratio is 4.5 compared to the industry median at 32.7. This means that it has a lower price relative to its earnings compared to its peers. This makes Vaso Corp more attractive for value investors.

Vaso Corp’s price-to-book ratio is higher than its peers. This could make Vaso Corp less attractive for value investors when compared to the industry median at 2.48.

You can read more about Vaso Corp’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Venus Concept Inc’s Value Grade

Value Grade:

Venus Concept Inc. is a global medical technology company. The Company develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. Its products and services include main console and applicators/handpieces, marketing supplies and kits, consumables and disposables, replacement applicators/handpieces, and others. It has developed and commercialized 11 technology platforms, including its ARTAS and NeoGraft systems. Its medical aesthetic technology platform is for a variety of indications, including treatment of facial wrinkles in certain skin types, temporary reduction of appearance of cellulite, non-invasive fat reduction (lipolysis) in the abdomen and flanks for certain body types and relief of minor muscle aches and pains in jurisdictions around the world. Venus Viva, Venus Viva MD, Venus Legacy, Venus Concept, Venus Versa, Venus Fiore, Venus Freedom, and others are trademarks of the Company.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Venus Concept Inc has a Value Score of 72, which is considered to be undervalued.

Venus Concept Inc’s price-to-book ratio is higher than its peers. This could make Venus Concept Inc less attractive for value investors when compared to the industry median at 2.48.

You can read more about Venus Concept Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Other Advanced Medical Equipment & Technology Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Advanced Medical Equipment & Technology stocks as well as other industrys.

Choosing Which of the 7 Best Advanced Medical Equipment & Technology Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

• BIOLASE Inc stock has a Value Grade of A.
• Hyperfine Inc stock has a Value Grade of B.
• Medigus Ltd - ADR stock has a Value Grade of B.
• Nuwellis Inc stock has a Value Grade of A.
• Precipio Inc stock has a Value Grade of B.
• Vaso Corp stock has a Value Grade of A.
• Venus Concept Inc stock has a Value Grade of B.

Now that you have a bit more background about each of the 7 undervalued stocks in the Advanced Medical Equipment & Technology industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Additional Resources About Advanced Medical Equipment & Technology Stocks

Want to learn more about Advanced Medical Equipment & Technology stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

• 7 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, January 12
• 3 Undervalued Advanced Medical Equipment & Technology Stocks for Wednesday, January 11
• 6 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, January 10
• 3 Undervalued Advanced Medical Equipment & Technology Stocks for Monday, January 09

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.